7
edits
Changes
Jump to navigation
Jump to search
mLine 24:
Line 24: + +
added info
This study indicates the inhibitory effect of hinokitiol on the migration of human adenocarcinoma A549 cells. The anticancer properties of hinokitiol are supported by the evaluation of results in the present study, including an increase of Bax/p53 and cytochrome c, and further activation of caspases-9/-3 and antioxidant enzymes CAT and SOD. Moreover, we discovered the inhibitory impact of hinokitiol on the A549 cell migration was accompanied through the downregulation of MMPs-9 and MMP-2. These outcomes can also illustrate a new therapeutic value of hinokitiol in anticancer therapy.
This study indicates the inhibitory effect of hinokitiol on the migration of human adenocarcinoma A549 cells. The anticancer properties of hinokitiol are supported by the evaluation of results in the present study, including an increase of Bax/p53 and cytochrome c, and further activation of caspases-9/-3 and antioxidant enzymes CAT and SOD. Moreover, we discovered the inhibitory impact of hinokitiol on the A549 cell migration was accompanied through the downregulation of MMPs-9 and MMP-2. These outcomes can also illustrate a new therapeutic value of hinokitiol in anticancer therapy.
Furthermore, another research showed strong anticancer characteristics of Hinokitiol by increasing the cytotoxicity against cervical cancer cells and non-small cell lung cancer (NSCLC) cells. Most cancers cell deaths are medicated through caspase-3 in apoptosis and consequently enlarged lysosomes which are regarded as possession of anticancer compounds and that can possibly result in lysosomal injury and increased autophagy followed by severe cell death. The choice of therapeutic to hinokitiol, a herbal product derivative, can be concluded to have a mechanism of action against NSCLC with minimum cytotoxic and maximized therapeutic effects.[http://www.kjcls.org/journal/view.html?doi=10.15324/kjcls.2019.51.2.221 [19<nowiki>]</nowiki>]